Skip to main content
SpringerLink
Log in

CUP und entitätenübergreifende Ansätze in der personalisierten Krebstherapie

Therapie des Cancer of Unknown Primary

  • fortbildung
  • Published:
InFo Onkologie Aims and scope

Trotz aller Fortschritte in Diagnostik und Therapie handelt es sich beim CUP(Cancer of Unknown Primary)-Syndrom weiterhin um eine Erkrankung mit einer insgesamt schlechten Prognose. Unter multimodalen Therapiekonzepten konnte bei prognostisch günstigen Subgruppen das mittlere Überleben bereits deutlich gesteigert werden. Neueste Therapieansätze im Sinne einer primärtumorunabhängigen Therapie lassen auch auf eine Verbesserung der Prognose beim weit disseminierten CUP-Syndrom hoffen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Huebner G et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009;100(1):44–9.

    Article  CAS  PubMed  Google Scholar 

  2. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428–35.

    Article  PubMed  Google Scholar 

  3. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) (Herausgeber: CUP Syndrom — Krebserkrankungen mit unbekanntem Primärtumor. Leitlinie: Stand 2014. https://www.onkopedia.com/de/onkopedia/guidelines/cup-syndrom-krebserkrankungen-mit-unbekanntem-primaertumor/@@view/html/index.html abgerufen am 15.05.2018.

  4. Zaun G et al. CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor. Dtsch Arztebl Int. 2018;115(10):157–62.

    PubMed Central  PubMed  Google Scholar 

  5. Löffler H et al. Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma. Dtsch Arztebl Int. 2014;111(27-28):481–7.

    PubMed  PubMed Central  Google Scholar 

  6. Schmidt T, Ulrich A. [Surgical options in cancer of unknown primary (CUP)]. Radiologe. 2014;54(2):140–4.

    Article  CAS  PubMed  Google Scholar 

  7. Krämer A, Löffler H. Prognostic Factors and Their Role in the Management of CUP Cancer of unknown primary. In: Krämer A, Löffler H, Herausgeber. Cancer of Unknown Primary Cham, Schweiz: Springer International Publishing; 2016. Seiten 45–65.

    Chapter  Google Scholar 

  8. Krug D et al. [Radiotherapeutic concepts in cancer of unknown primary site]. Radiologe. 2014;54(2):145–51.

    Article  CAS  PubMed  Google Scholar 

  9. Hainsworth JD et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010;16(1):70–5.

    Article  CAS  PubMed  Google Scholar 

  10. Neben K et al. Metastases in the absence of a primary tumor: advances in the diagnosis and treatment of CUP syndrome. Dtsch Arztebl Int. 2008;105(43):733–40.

    PubMed  PubMed Central  Google Scholar 

  11. Greco FA et al. Carcinoma of unknown primary site (CUP): outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy. J Clin Oncol. 2011;29(15_suppl);Abstr 3563.

    Article  Google Scholar 

  12. Richardson RL et al. The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med. 1981;94(2):181–6.

    Article  CAS  PubMed  Google Scholar 

  13. Poeppel TD et al. Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin. 2015;54(1):1–11.

    PubMed  CAS  Google Scholar 

  14. Hyman DM et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Massard C et al. High-throughput genomics and clinic al outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–95.

    Article  CAS  PubMed  Google Scholar 

  16. Massard C et al. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer. 2007; 97(7):857–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hainsworth JD et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007;25(13):1747–52.

    Article  CAS  PubMed  Google Scholar 

  18. Krämer A et al. Carcinoma of Unknown Primary - an Orphan Disease? Breast Care (Basel). 2008;3(3):164–70.

    Google Scholar 

  19. Garon EB et al. Pembrolizumab for the treatment of non—small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.

    Article  PubMed  Google Scholar 

  20. Gröschel S et al. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud. 2016;2(6):a001180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Le DT et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Deutschland

    Gregor Zaun, Stefan Kasper & Martin Schuler

  2. Deutsches Konsortium für Translationale Krebsforschung (DKTK) Partnerstandort Universitätsklinikum Essen, Essen, Deutschland

    Martin Schuler

  3. Innere Klinik (Tumorforschung), Universitätsklinikum Essen (AöR), Hufelandstraße 55, 45147, Essen, Deutschland

    Gregor Zaun

Authors
  1. Gregor Zaun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregor Zaun.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaun, G., Kasper, S. & Schuler, M. Therapie des Cancer of Unknown Primary. Info Onkol. 21 (Suppl 1), 44–48 (2018). https://doi.org/10.1007/s15004-018-6137-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-018-6137-x

Search

Navigation